≥99% HPLCPre-filled pen

Tirzepatide

Name: Tirzepatide
Brand: Dripfy
Availability: InStock

What it is?

Tirzepatide is a dual incretin receptor agonist studied for GLP-1 and GIP pathway engagement in metabolic regulation. It is positioned for protocols targeting glycaemic control, appetite signalling, and body-weight reduction endpoints through coordinated endocrine modulation.

Dripfy Advantage

Receptor engagement: Activates GLP-1 and GIP receptors, supporting multi-pathway incretin signalling relevant to metabolic control.
Appetite & satiety signalling: Associated with central mechanisms that reduce hunger drive and enhance satiety-related behavioural endpoints.
Glucose–insulin dynamics: Supports improved insulin sensitivity markers and glucose regulation endpoints in structured metabolic models.
Energy balance modulation: Positioned to influence energy intake–expenditure balance, supporting fat-mass reduction endpoints over time.

Clinical Applications & Therapeutic Potential

Weight-management endpoints: Potential support for body-weight reduction and fat-mass shift markers in controlled protocols.
Metabolic health markers: Potential improvements in glycaemic control endpoints and insulin sensitivity markers (context-dependent).
Cardiometabolic profile support: Potential downstream benefits across lipid-related markers and broader cardiometabolic risk parameters.
Lean-mass preservation focus: Frequently positioned within protocols that track fat-to-lean ratio endpoints during weight-reduction phases.

Composition & Formulation

Class: Dual incretin receptor agonist peptide (GIP/GLP-1 pathway class)
Format: Ready-to-use pre-filled pen

€1,007

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Tirzepatide

Dual GIP/GLP-1 receptor agonist · Pre-filled pen

A· Strong evidence

Tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors. Through this combined incretin signalling it enhances glucose-dependent insulin secretion, reduces appetite and slows gastric emptying. These actions support the improvements in glycaemic control and body weight demonstrated in large randomised trials.

Studied use areas

Type 2 diabetes glycaemic control
Weight management and body-composition endpoints
Appetite and satiety regulation
Metabolic parameters such as HbA1c and lipids

Safety & status

Prescription-only medicine in the EU and UK (EMA/MHRA); it must be prescribed and supervised by a physician
Gastrointestinal effects (nausea, diarrhoea, vomiting) are common, particularly during dose escalation
Requires medical screening (e.g. history of pancreatitis or certain thyroid tumours) and is not for use in pregnancy
Dose, titration and treatment duration are individualised and set by the treating physician

⚕ Clinical note: This is educational information, not medical advice. Tirzepatide is a prescription-only medicine; any use must be initiated and monitored by a qualified physician, who assesses suitability, benefits and risks individually.

Evidence: Grade A — approved medicine supported by large randomised controlled trials · References: Dual incretin (GIP/GLP-1) receptor agonist randomised controlled trials; EMA/MHRA product information for incretin-based medicines; Peer-reviewed diabetes and obesity-medicine literature